• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Gabapentin monotherapy as effective as gabapentin plus antidepressant in treatment of hot flashes

Article

A phase 3 study evaluating the use of gabapentin alone and in combination with an antidepressant in women with hot flashes who had an inadequate response with antidepressant monotherapy demonstrated that gabapentin reduced hot flashes by approximately 50%, whereas the combination of an anti-depressant with gabapentin appeared to offer no additional benefit.

Related Content
How Magellan’s Behavior Health Program Saved up to $4,300 PMPY

How Magellan’s Behavior Health Program Saved up to $4,300 PMPY

November 7th 2023
Article

Using an AI platform, Magellan Health was able to better support providers in prescribing behavioral health medications and addressing medication problems, which reduced pharmacy costs and increased adherence.

FDA Approves Extended-Release Therapy for Major Depression

FDA Approves Extended-Release Therapy for Major Depression

September 28th 2023
Article

Exxua is approved to treat adults with major depressive disorder, but its labeling does not contain warnings about sexual function or weight gain.

FDA Approves First Nonprescription Oral Contraceptive

FDA Approves First Nonprescription Oral Contraceptive

July 13th 2023
Article

Opill will be available in stores and online in the first quarter of 2024.

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

March 29th 2023
Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

FDA Accepts NDA for Zuranolone for Depression

FDA Accepts NDA for Zuranolone for Depression

February 6th 2023
Article

Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.

FDA Approves Vraylar for Major Depressive Disorder

FDA Approves Vraylar for Major Depressive Disorder

December 20th 2022
Article

This is the fourth indication for Vraylar, a dopamine and serotonin partial agonist that can now be used as an adjunctive therapy in patients with major depressive disorder.

© 2024 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact